OmniAb, Inc. (OABI)

OmniAb, Inc. has experienced a significant decline in its stock price, decreasing by 57.94% between November 19, 2024, and November 18, 2025. Key events include the release of the Second Quarter 2025 financial results, which showed a decrease in revenue, the release of the Third Quarter 2025 financial results, the announcement of a new technology license and services agreement with an incubated company, and participation in three investor conferences in November 2025.

The available information does not contain specific details regarding demand seasonality for OmniAb, Inc.'s products and services. Demand is more influenced by the pace of drug discovery and development in the biopharmaceutical industry rather than seasonal consumer patterns.

OmniAb, Inc. is a biotechnology company specializing in the discovery and development of therapeutic antibodies, operating within the Medical sector. The company licenses its proprietary antibody discovery platform to pharmaceutical, biotech companies, and academic institutions. Its integrated OmniAb platform uses transgenic animal models and computational tools to generate human and humanized antibodies. The company offers fee-for-service collaborations and license agreements across various therapeutic areas.

OmniAb, Inc. serves a global client base, licensing its technology to partners in the United States, Europe, Japan, China, and Canada. The company maintains research facilities in North America and Europe and is headquartered in Emeryville, California.

OmniAb scored higher than 70% of companies evaluated by MarketBeat and ranked 252nd out of 941 stocks in the medical sector, suggesting a relatively positive standing within its industry.

Institutional ownership in OmniAb, Inc. is substantial, with 72.08% of the stock held by institutions. Insiders hold 8.60% of the company's stock, and in the past three months, insider buying has exceeded selling, with $107,707.00 in purchases and $0.00 in sales.